Literature DB >> 14612971

Telomerase in intracranial meningiomas.

L Boldrini1, S Pistolesi, S Gisfredi, S Ursino, G Lupi, M Caniglia, R Pingitore, F Basolo, G Parenti, G Fontanini.   

Abstract

Telomere length maintenance is essential for tumorigenesis; most human tumors stabilize their chromosome ends via the activity of a specialized reverse transcriptase, telomerase, that uses the template region of the RNA moiety complementary to the TTAGGG repeat to synthesize one strand of telomeric DNA. Meningiomas are estimated to constitute between 13% and 26% of primary intracranial tumors. The aim of this study was to evaluate telomerase activity and its messenger expression in meningiomas in relation to their different histologic pattern and grade of cytonuclear atypies, which are associated with relapse, and consequently represent the most important parameter for the evaluation of the clinical behavior of this tumor. Telomerase activity was examined by the telomeric repeat amplification protocol (TRAP) assay in 32 meningiomas (26 typical and 6 atypical/anaplastic). Telomerase messenger expression (hTERT mRNA) was evaluated by reverse transcription-PCR analysis in the same group of tumors. Telomerase activity ranged from undetectable to low levels in 19/26 (73%) of typical meningiomas, while all the atypical/anaplastic meningiomas showed medium-high levels of activity (>3 TPG units, median value), (chi(2) test; p=0.001). The levels of telomerase in terms of its messenger level expression overlapped the activity; a significant association between telomerase activity and hTERT mRNA expression was also found (chi(2) test; p=0.01). Moreover, 2 atypical/anaplastic meningiomas of our series relapsed; in these samples we found high levels of telomerase, both in terms of activity and mRNA expression. Telomerase activity and its hTERT mRNA expression tended to increase as the histologic grading of intracranial tumors increased, suggesting a role of telomerase reactivation in the progression of these tumors. Moreover, our results indicate RT-PCR assay as a rapid tool to identify and quantify telomerase RNA in intracranial meningiomas as in other human tumor models.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612971     DOI: 10.3892/ijmm.12.6.943

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

Review 1.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

2.  hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas.

Authors:  Gina Fürtjes; Michaela Köchling; Susanne Peetz-Dienhart; Andrea Wagner; Katharina Heß; Martin Hasselblatt; Volker Senner; Walter Stummer; Werner Paulus; Benjamin Brokinkel
Journal:  J Neurooncol       Date:  2016-07-27       Impact factor: 4.130

3.  Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.

Authors:  Marianne F James; Johanna M Lelke; Mia Maccollin; Scott R Plotkin; Anat O Stemmer-Rachamimov; Vijaya Ramesh; James F Gusella
Journal:  Neurobiol Dis       Date:  2007-09-19       Impact factor: 5.996

4.  TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.

Authors:  Sabine Spiegl-Kreinecker; Daniela Lötsch; Katharina Neumayer; Lucia Kastler; Johannes Gojo; Christine Pirker; Josef Pichler; Serge Weis; Rajiv Kumar; Gerald Webersinke; Andreas Gruber; Walter Berger
Journal:  Neuro Oncol       Date:  2018-11-12       Impact factor: 12.300

5.  mRNA quantification and clinical evaluation of telomerase reverse transcriptase subunit (hTERT) in intracranial tumours of patients in the island of Crete.

Authors:  A Yannopoulos; E Dimitriadis; A Scorilas; T Trangas; E Markakis; M Talieri
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.